BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference

BerGenBio Reports Second Quarter 2023 Financial Results

BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung Cancer

BerGenBio ASA: Invitation to second quarter and half year 2023 results webcast

BerGenBio ASA: Share capital increase registered

BerGenBio ASA - Information about the Warrants issued in connection with the Rights Issue

BerGenBio Reports First Quarter 2023 Financial Results and Provides Business Update

BerGenBio ASA – Correction of final results of the Rights Issue

BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO